Science Corporation’s vision-restoring chip wins EU approval

Science Corporation won EU approval for its vision-restoring chip, according to TechCrunch. The decision clears a regulated path for the device in Europe and puts the company under a commercial bar that CEO Max Hodak named outright: the field needs a company making $100 million a year of revenue.

The product is a vision-restoring implant, not a software-only therapy. EU approval means the chip cleared regional safety and performance requirements for clinical use, so deployment now turns on surgical workflows, patient selection, device durability, and how well outcomes hold up outside trial settings.

For engineers and builders, that approval is a systems milestone as much as a medical one. Hardware that interfaces with neural tissue has to stay reliable in the body, stay supportable in clinics, and still point at a business that can reach the $100 million revenue level Hodak described. Power, packaging, firmware, and long-term data capture all become product requirements, not lab extras.

Competitors in vision restoration face the same pressure. Regulatory clearance alone does not create a market leader; Hodak’s $100 million revenue target frames success as sustained commercial scale, not a one-time approval headline. Whoever converts implants into repeatable, paid clinical volume first will set the bar for the rest of the category.

Watch how Science Corporation turns EU clearance into real implant volume, clinic partnerships, and revenue growth toward that $100 million mark. The next signal that matters is not another announcement of approval, but evidence that the chip is being used at scale and paid for at a level that can support the company.